From the first launch to ongoing market access operational execution, IntegriChain solves some of the most complex and pressing challenges associated with drug commercialization. We deliver pharma’s only comprehensive data, consulting, and business process platform for market access departments, providing the strategy, data, applications, and infrastructure for therapy commercialization.
Solutions overview
IntegriChain delivers the pharmaceutical industry’s largest and only data and business process platform for therapy commercialization and access. Manufacturers rely on our analytics, applications, and managed services to power their operations and harness the value of their channel, patient and payer data.
View all products
IntegriChain provides a complete set of professional services for commercialization and market access execution–from life science strategy and operational consulting to implementation, integration, migrations, and analytics.
Services overview
We help all stakeholders in the pharmaceutical industry drive access with our relentless focus on unifying all of the critical business functions for therapy commercialization and access – contracts & pricing, gross-to-net, channel, and patient services – to unlock strategic payer, provider, pharmacy and patient access insights.
Learn more about our company
Learn more about joining our growing IntegriChain team of data scientists, market access experts, analysts, and consulting professionals – our culture, our purpose, our teams in the US and Pune. Check out our careers or keep in touch for future opportunities.
Careers overview
January 24, 2023 – 1:00 PM EST
Our industry continues to grapple with the extensive drug pricing reform components of the Inflation Reduction Act of 2022. IntegriChain has been working with manufacturers across the industry to understand how this legislation will impact all types of product archetypes and companies of all sizes.
In this webinar, Jeff Baab, Vice President, Operational Consulting and Benjamin Fanelli, Senior Manager, Government Pricing, will recap the key provisions of the Inflation Reduction Act and share some real world examples to illustrate how manufacturers are attempting to operationalize these provisions and account for the financial implications.
In case you missed it, read Jeff Baab’s initial blog on the impacts of the Inflation Reduction Act on the pharmaceutical industry.
LEARN MORE
Jeff BaabVice President, Operational Consulting
Benjamin Fanelli Senior Manager, Government Pricing
